SEC Comment Letter 0000000000-24-007074 to Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc.
Date: June 21, 2024 · CIK: 0001750149 · Accession: 0000000000-24-007074
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280317
Letter
United States securities and exchange commission logo June 21, 2024 Milton Werner Chief Executive Officer Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA 30339 Re:Inhibikase Therapeutics, Inc. Registration Statement on Form S-1 Filed June 18, 2024 File No. 333-280317 Dear Milton Werner: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Todd Kornfeld
Show Raw Text
United States securities and exchange commission logo
June 21, 2024
Milton Werner
Chief Executive Officer
Inhibikase Therapeutics, Inc.
3350 Riverwood Parkway SE, Suite 1900
Atlanta, GA 30339
Re:Inhibikase Therapeutics, Inc.
Registration Statement on Form S-1
Filed June 18, 2024
File No. 333-280317
Dear Milton Werner:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Todd Kornfeld